# Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

> **NCT06456138** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 60 (estimated)

## Conditions studied

- KRAS Mutation-Related Tumors
- Advanced Lung Cancer
- Refractory Tumor

## Interventions

- **DRUG:** Trametinib
- **DRUG:** Anlotinib
- **DRUG:** Tislelizumab

## Key facts

- **NCT ID:** NCT06456138
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-06-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06456138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06456138, "Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06456138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*